Hikma Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Hikma Pharmaceuticals
Public company
Traded asLSEHIK
Founded1978; 41 years ago (1978)
HeadquartersLondon, UK
Key people
Said Darwazah, Chairman
Siggi Olafsson, CEO
RevenueUS$2,076 million (2018)[1]
US$460 million (2018)[1]
US$285 million (2018)[1]

Hikma Pharmaceuticals is a multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded in Amman, Jordan in 1978 by Samih Darwazah. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.


The company was founded by Samih Darwazah in 1978 in Amman, Jordan.[2] In August 1996 it became the first Arab company to export pharmaceutical products to the United States.[3] It was first listed on the London Stock Exchange in 2005.[2] Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005[4] and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006.[2] In 2007 the Company went on to buy APM in Jordan,[5] Alkan Pharma in Egypt, APM and Al Jazeera Pharma in Saudi Arabia[5] Thymoorgan in Germany[2] and Ribosepharm in Germany.[2] It started to acquire Baxter Healthcare Corporation's US generic injectables business, Multi-Source Injectables or MSI, and completed the transaction in May 2011.[6]

In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco.[7] Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma’s second venture in Algeria after Hikma Pharma Algeria.[8]

In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company.[9]

Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) in 2012.[10] In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement with MIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market.[11]

On 28 May 2014, Hikma Pharmaceuticals agreed to acquire assets from the U.S. generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.[12]


Hikma Pharmaceuticals' head office in Hanover Square in London (on the left)

Hikma Pharmaceutical’s operations span 29 manufacturing plants in 11 countries: United States, Portugal, Italy, Jordan, Saudi Arabia, Algeria, Germany, Egypt, Morocco, Tunisia and Sudan.[13]

Business Segments[edit]


Hikma’s branded business segment comprises the development and sales of branded generics and in-licensed patented products in the MENA region. Hikma has 499 products in 1,256 dosage strengths. Top products include Actos, Amoclan, Blopress, Omnicef, Prograf and Suprax.[14]


Hikma sells specialized injectable products in the US, Europe and MENA including argatroban, fentanyl, phenylephrine, robaxin and iron gluconate. The company sells 200 products in 379 dosage forms and strengths.[14]


Hikma’s oral generic products are sold in the US and include such products as amoxicillin, cephalexin, doxycycline, methocarbamol and prednisone.[14]

See also[edit]


  1. ^ a b c "Preliminary Results 2018" (PDF). Hikma Pharmaceuticals. Retrieved 14 March 2019.
  2. ^ a b c d e Hikma History
  3. ^ "Economy - Sectoral Analysis". kinghussein.gov.jo. Retrieved 6 March 2015.
  4. ^ "Jordanian Pharma Major Buys Into An American Healthcare Startup". INC Arabia. 24 October 2016. Retrieved 18 April 2017.
  5. ^ a b Hikma Annual Report 2007 Page 15
  6. ^ "Hikma Pharmaceuticals Plc Completes Acquisition of Baxter Healthcare Corporation's Multi-Source Injectables Business". Reuters. Retrieved 3 May 2011. Italic or bold markup not allowed in: |work= (help)
  7. ^ Hikma Pharmaceuticals PLC (3 October 2011). "Hikma Enters the Moroccan Market Through the Acquisition of 63.9% of Promopharm and... -- LONDON, October 3, 2011 /PRNewswire/ --". prnewswire.com. Retrieved 6 March 2015.
  8. ^ "Hikma expands in Algeria with Al Dar Al Arabia acquisition". Manufacturing Chemist. 15 April 2011. Retrieved 18 April 2017.
  9. ^ "Login - Evaluate". evaluatepharma.com. Retrieved 6 March 2015.
  10. ^ "Hikma expands in Egypt with EPCI acquisition". pmlive.com. 10 January 2013. Retrieved 6 March 2015.
  11. ^ "Hikma sets up JV to enter Ethiopia". PharmaTimes. 18 September 2013. Retrieved 18 April 2017.
  12. ^ "Hikma buys Boehringer injectable drugs business for up to $300 mln". Reuters. 28 May 2014. Retrieved 6 March 2015.
  13. ^ "Our global presence". Retrieved 18 April 2017.
  14. ^ a b c "Products". Hikma Pharmaceuticals. Retrieved 18 April 2017.

External links[edit]